P/E ratio for Lexicon Pharmaceuticals (LXRX)
P/E ratio as of April 2024 (TTM): -2.32
According to Lexicon Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.32353. At the end of 2022 the company had a P/E ratio of -3.13.
P/E ratio history for Lexicon Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.13 | -51.52% |
| 2021 | -6.46 | 3.87% |
| 2020 | -6.22 | -282.8% |
| 2019 | 3.40 | -158.91% |
| 2018 | -5.77 | -28.7% |
| 2017 | -8.10 | -19.78% |
| 2016 | -10.1 | -96.21% |
| 2015 | -266 | 5602.54% |
| 2014 | -4.67 | -48.13% |
| 2013 | -9.00 | -10.41% |
| 2012 | -10.0 | 172.55% |
| 2011 | -3.69 | -10.42% |
| 2010 | -4.11 | 40.37% |
| 2009 | -2.93 | 17.24% |
| 2008 | -2.50 | -49.67% |
| 2007 | -4.97 | 11.45% |
| 2006 | -4.46 | -30.4% |
| 2005 | -6.40 | -38.94% |
| 2004 | -10.5 | 102.96% |
| 2003 | -5.17 | 24.52% |
| 2002 | -4.15 | -74.83% |
| 2001 | -16.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Thermo Fisher Scientific TMO | 37.4 | -1,709.29% | 🇺🇸 USA |
 Illumina ILMN | -4.60 | 97.77% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 23.6 | -1,117.43% | 🇺🇸 USA |
 Ultragenyx RARE | -4.32 | 85.94% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | 44.9 | -2,034.51% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | -0.6738 | -71.00% | 🇺🇸 USA |
 Aerie Pharmaceuticals AERI | -20.3 | 775.10% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 104 | -4,572.03% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | -0.3174 | -86.34% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.